02:42 PM EDT, 03/13/2026 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

ImmunityBio ( IBRX ) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.

The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio ( IBRX ) added.

10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio ( IBRX ) said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.

ImmunityBio ( IBRX ) also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.

Price: 8.47, Change: +0.65, Percent Change: +8.25